Ponesimod
- TRADE NAME: Ponvory (Janssen)
- INDICATIONS: Treatment of relapsing forms of multiple sclerosis.
- CLASS: Sphingosine1-phosphate receptor modulator
- HALF-LIFE: ~33 hours
FDA APPROVAL DATE: 03/18/2021
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:Alemtuzumab, Amiodarone, anti-arrhythmic drugs, QT prolonging drugs, drugs that may decrease heart rate , attenuated vaccines, beta-blockers, Carbamazepine, Carbamazepine, CYP3A4 and UGT1A1 inducers, Digoxin, Diltiazem, Phenytoin, Procainamide, Quinidine, Rifampin, Sotalol, Verapamil
May cause fetal harm. Contraception is advised.
Please login to see the rest of this drug profile
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GENITOURINARY.
NEUROMUSCULAR/SKELETAL.
RESPIRATORY.
Page last updated 07/31/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric